icon-    folder.gif   Conference Reports for NATAP  
  XIX International AIDS Conference
July 22-27, 2012
Washington, DC
Back grey_arrow_rt.gif
A randomized trial to estimate efficacy and safety of 2 doses of raltegravir and efavirenz for treatment of HIV-TB co-infected patients : ANRS 12 180 REFLATE TB trial.
  Reported by Jules Levin
19th Intl AIDS Conf Wash DC July 22-27 2012
B. Grinsztejn1, N. De Castro2,3, V. Arnold4, V. Veloso1, M. Morgado5, JH. Pilotto6, C. Brites7, JV. Madruga8, N. Barcellos9, BR Santos10, C. Vorsatz1, C. Grondin4, M. Santini-Oliveira1, O. Patey11, C. Delaugerre2,3, G. Chene4, J-M. Molina2,3 and the ANRS 12 180 Reflate TB study group. 1 Laboratory of Clinical Research on STD/AIDS, IPEC, Fiocruz, Rio de Janeiro, Brazil, 2 University of Paris Diderot, Sorbonne Paris Cite, INSERM U941, 3 Hospital Saint-Louis, APHP, France, 4 INSERM U897 and University Bordeaux Segalen, 5 Laboratory of AIDS and Molecular Immunology, Fiocruz, Rio de Janeiro, Brazil, 6 Department of STD/AIDS, Nova Iguacu, Brazil, 7 Laboratory of Research in Infectious Diseases, Salvador de Bahia, Brazil, 8 Research Unit for Treatment of STD/AIDS, Sao Paulo, Brazil, 9 Department of Care and Therapy, Porto Alegre, Brazil, 10 Department of Infectious Diseases, Porto Alegre, Brazil, 11 Department of Internal and Tropical Medicine, Villeneuve St George, France.